4D Molecular Therapeutics, Inc. Stock-Based Compensation
4D Molecular Therapeutics, Inc. (FDMT) reported Stock-Based Compensation of $10.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.88M, a 18.68% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $4.45M, a 36.26% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.55M, a 26.72% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.52M, a 30.37% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $22.02M, a 15.70% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $26.12M, a 32.80% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $19.66M, a 14.86% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $17.12M, a 24.07% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $10.34M 10-Q · filed 2026-08-13 | $15.89M derived: sum of 3 quarters · filed 2026-08-13 | $20.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.45M 10-Q · filed 2026-05-07 | $10.01M derived: sum of 2 quarters · filed 2026-05-07 | $14.53M derived: sum of 3 quarters · filed 2026-05-07 | $19.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $10.07M derived: sum of 2 quarters · filed 2026-03-18 | $15.03M derived: sum of 3 quarters · filed 2026-08-13 | $22.02M 10-K · filed 2026-03-18 |
| 2025-09-30 | $4.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $9.48M derived: sum of 2 quarters · filed 2026-08-13 | $16.46M 10-Q · filed 2025-11-10 | $24.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $11.94M 10-Q · filed 2026-08-13 | $19.52M derived: sum of 3 quarters · filed 2026-08-13 | $26.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $6.99M 10-Q · filed 2026-05-07 | $14.56M derived: sum of 2 quarters · filed 2026-05-07 | $21.05M derived: sum of 3 quarters · filed 2026-05-07 | $27.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $14.07M derived: sum of 2 quarters · filed 2026-03-18 | $20.14M derived: sum of 3 quarters · filed 2026-03-18 | $26.12M 10-K · filed 2026-03-18 |
| 2024-09-30 | $6.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $12.56M derived: sum of 2 quarters · filed 2025-11-10 | $18.54M 10-Q · filed 2025-11-10 | $24.45M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $6.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $12.05M 10-Q · filed 2025-08-11 | $17.96M derived: sum of 3 quarters · filed 2025-08-11 | $22.52M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $5.97M 10-Q · filed 2025-05-08 | $11.89M derived: sum of 2 quarters · filed 2025-05-08 | $16.45M derived: sum of 3 quarters · filed 2025-05-08 | $21.42M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $10.47M derived: sum of 2 quarters · filed 2025-02-28 | $15.44M derived: sum of 3 quarters · filed 2025-02-28 | $19.66M 10-K · filed 2025-02-28 |
| 2023-09-30 | $4.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $9.53M derived: sum of 2 quarters · filed 2024-11-13 | $13.75M 10-Q · filed 2024-11-13 | $18.10M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $4.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.19M 10-Q · filed 2024-08-08 | $13.54M derived: sum of 3 quarters · filed 2024-08-08 | $18.06M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.22M 10-Q · filed 2024-05-09 | $8.57M derived: sum of 2 quarters · filed 2024-05-09 | $13.09M derived: sum of 3 quarters · filed 2024-05-09 | $17.41M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $8.87M derived: sum of 2 quarters · filed 2024-02-29 | $13.19M derived: sum of 3 quarters · filed 2024-02-29 | $17.12M 10-K · filed 2024-02-29 |
| 2022-09-30 | $4.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $8.84M derived: sum of 2 quarters · filed 2023-11-09 | $12.78M 10-Q · filed 2023-11-09 | $16.51M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $8.26M 10-Q · filed 2023-08-09 | $11.99M derived: sum of 3 quarters · filed 2023-08-09 | $15.91M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $3.93M 10-Q · filed 2023-05-11 | $7.66M derived: sum of 2 quarters · filed 2023-05-11 | $11.59M derived: sum of 3 quarters · filed 2023-05-11 | $15.40M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $7.65M derived: sum of 2 quarters · filed 2023-03-15 | $11.47M derived: sum of 3 quarters · filed 2023-03-15 | $13.80M 10-K · filed 2023-03-15 |
| 2021-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $7.74M derived: sum of 2 quarters · filed 2022-11-08 | $10.07M 10-Q · filed 2022-11-08 | $11.79M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $3.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $6.14M 10-Q · filed 2022-08-11 | $7.86M derived: sum of 3 quarters · filed 2022-08-11 | $9.01M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.33M 10-Q · filed 2022-05-12 | $4.05M derived: sum of 2 quarters · filed 2022-05-12 | $5.19M derived: sum of 3 quarters · filed 2022-05-12 | $6.23M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $2.86M derived: sum of 2 quarters · filed 2022-03-28 | $3.90M derived: sum of 3 quarters · filed 2022-03-28 | $4.98M 10-K · filed 2022-03-28 |
| 2020-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.18M derived: sum of 2 quarters · filed 2021-11-10 | $3.27M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.12M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.08M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $3.54M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |